IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$4.79
-0.15 (-3.04%)
▼
5d:
-6.81%
30d:
+12.18%
90d:
+149.48%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Feb 26, 2026
21d
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.63
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.60
27.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $4.79, which is considered slightly high relative to its 30-day fair value range of $3.84 to $5.10. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.6) compared to its historical average (6.4). Remarkably, the market is currently pricing in an annual earnings decline of 4.2% over the next few years. This pessimistic expectation contrasts with the company's recent 1046.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $4.58, while resistance sits at $5.57. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $4.58, while resistance sits at $5.57. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$3.84 -
$5.10
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- NEUTRAL: Near Wall St target ($4.85)
- CAUTION: 5-day price weakness (-6.8%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$3.84 -
$5.10
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.58
Resistance Level
$5.57
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
5.61
Wall Street Target
$4.85
(+1.3%)
Revenue Growth (YoY)
33.3%
Earnings Growth (YoY)
1046.8%
Profit Margin
8.4%
Valuation Discount vs History
-4.2% cheaper
PE vs Historical
5.6 vs 6.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.2%
(market-implied from PE analysis)
1-Year Target
$4.59
(-4%)
2-Year Target
$4.40
(-8%)
3-Year Target
$4.21
(-12%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
$4.80
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 234.6%)
$64.22
(+1241%)
Base:
(SPY PE: 5.6, Growth: 234.6%)
$16.17
(+238%)
Bear:
(PE: 4.8, Growth: 234.6%)
$13.74
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 27.44 | Current EPS (TTM): $0.18
Bull Case
$10.87
(+127%)
Analyst growth 100.0%, PE expands to 30.2
Base Case
$9.88
(+106%)
Market implied 100.0%, PE stable at 27.4
Bear Case
$3.36
(-30%)
Severe decline -20.0%, PE contracts to 23.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.6 to 6.4
Stabilization Target:
$5.46
(+14.0%)
PE Expansion Potential:
+14.0%
Last updated: February 04, 2026 9:14 AM ET
Data refreshes hourly during market hours. Next update: 10:14 AM
Data refreshes hourly during market hours. Next update: 10:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$37 | 59 HOLD |
